HepTcell as Immunotherapy to Achieve Functional Cure for Chronic HBV

Time: 2:00 pm
day: Day Two


• Chronic hepatitis B is characterized by immune tolerance, and functional cure can only be achieved by restoring T cell function

• T cell epitopes from Core and Polymerase antigens, conserved across HBV genotypes represent attractive targets for the development of safe and effective HBV immunotherapeutic

• An immunotherapeutic agent will be effective at an HBsAg level at which immune tolerance is reduced (below 100 IU/mL). Combination therapy with one of the new direct acting agents may achieve this starting point for treatment